Item 8.01. Other Events. On July 20, 2026, Oncolytics Biotech Inc. (the “Company”) issued a press release announcing pelareorep in combination with a checkpoint inhibitor was granted Fast Track Designation from the U.S.…
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically “cold” tumors “hot” through the activation of innate and adaptive immune responses.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events.
On July 20, 2026, Oncolytics Biotech Inc. (the “Company”) issued a press release announcing pelareorep in combination with a checkpoint inhibitor was granted Fast Track Designation from the U.S. Food and Drug Administration for the treatment of patients with inoperable, locally recurrent or metastatic squamous cell carcinoma of the anal canal who progressed on or were intolerant to one or more prior lines of systemic therapy. The information set forth in this Item 8.01 and in Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.
